# Moderna (MRNA) Q2 2026 earnings

Results filed 2026-07-31 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/mrna/2026-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/0001682852-26-000147-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Moderna is awaiting a U.S. decision on its seasonal flu vaccine mFLUSIVA, which would be its fifth product, after a unanimous advisory committee recommendation, while its norovirus vaccine missed an early-success bar.

Moderna's flu vaccine mFLUSIVA won a unanimous FDA advisory committee recommendation ahead of an August 5 decision date, and the flu-plus-COVID shot mCOMBRIAX gained European Commission authorization. mRESVIA was approved in Australia and Mexico and mNEXSPIKE in Japan and Taiwan. Europe added a joint procurement contract for up to 24 million mRESVIA doses on behalf of six countries, and a Brazil manufacturing collaboration supports COVID vaccine supply. The norovirus vaccine did not meet early-success criteria at its interim analysis.
Management is steering toward a broader, more diversified portfolio: flu approvals, international partnerships, and pivotal readouts in 2026 for intismeran in melanoma and for the propionic acidemia therapy. The tension is that growth depends on a few binary events, including the U.S. flu decision, FDA guidance on refiling the combination vaccine, and COVID vaccination rates that may keep falling, while the norovirus program now needs another cohort.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Total revenue | $145 million | compared to $142 million in the same period in 2025 | GAAP |
| Net loss | $(0.8) billion | an improvement of $43 million, or 5%, compared to the second quarter of 2025 | GAAP |
| Loss per share | $(1.97) | compared to $(2.13) for the second quarter of 2025 | GAAP |
| Loss from operations | (815) | compared to (907) in the second quarter of 2025 | GAAP |
| Cash, cash equivalents and investments | $6.9 billion | compared to $7.5 billion as of March 31, 2026 |  |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| U.S. revenue | $87 million |  |
| International revenue | $58 million |  |
| Net product sales | $94 | compared to $114 in the second quarter of 2025 |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Revenue growth from 2025 | 2026 | up to 10% |
| Share of second half revenue in the third quarter | second half of 2026 | approximately 55% |
| Cost of sales | 2026 | approximately $1.7 billion |
| Research and development expenses | 2026 | approximately $2.9 billion |
| Selling, general and administrative expenses | 2026 | approximately $1.0 billion |
| Capital expenditures | 2026 | $0.2 to $0.3 billion |
| Year-end cash and investments | year-end 2026 | $4.7 to $5.2 billion |

## Key takeaways

1. **mFLUSIVA could become Moderna's fifth approved product** The seasonal flu vaccine received a unanimous VRBPAC recommendation ahead of an August 5 PDUFA date. Approval would extend Moderna beyond COVID and RSV in the U.S.
2. **Norovirus vaccine missed early-success bar at interim** mRNA-1403 did not meet statistical criteria for early success in Phase 3. The trial remains blinded and Moderna is preparing to enroll an additional cohort, which delays any answer.
3. **International partnerships and approvals widen the commercial base** Moderna signed a joint EU procurement contract for up to 24 million mRESVIA doses and a Brazil manufacturing collaboration for COVID vaccines. New approvals came in Australia, Mexico, Japan and Taiwan.
4. **Combination flu and COVID vaccine advances outside the U.S.** mCOMBRIAX received European Commission authorization and mRNA-1083 filings are under review in Japan, Canada and Australia. In the U.S., Moderna is still awaiting FDA guidance on refiling.
5. **Intismeran oncology program expands toward pivotal data** Nine Phase 2 and Phase 3 trials with Merck are underway, and five-year Phase 2b melanoma data showed a 49% lower risk of recurrence or death versus KEYTRUDA alone. Phase 3 adjuvant melanoma data are potentially due in 2026.

## Questions

**What is the next major U.S. catalyst for Moderna's product portfolio?** The FDA decision on mFLUSIVA, its seasonal flu vaccine, with a PDUFA date of August 5, 2026. Approval would make it Moderna's fifth approved product.
**What happened with Moderna's norovirus vaccine?** Phase 3 mRNA-1403 did not meet statistical criteria for early success at the interim analysis. The trial is ongoing and blinded while Moderna works toward enrolling an additional cohort.
**Where is Moderna expanding its vaccine business outside the U.S.?** It signed a joint EU procurement contract for up to 24 million mRESVIA doses for six countries and a Brazil manufacturing collaboration for COVID vaccines. It also received approvals in Australia, Mexico, Japan and Taiwan.
**What is the status of Moderna's flu plus COVID combination vaccine?** mCOMBRIAX is authorized in the EU, and mRNA-1083 filings are under review in Japan, Canada and Australia. Moderna is awaiting FDA guidance on refiling in the U.S.
**What pivotal readouts is Moderna expecting in 2026?** Phase 3 adjuvant melanoma data for intismeran, developed with Merck, and registrational data for its propionic acidemia therapy mRNA-3927. Moderna deferred a pivotal trial decision on its methylmalonic acidemia candidate until the PA readout.

